64293 Darmstadt, de
+49 (6151) 325100
Zedira: BMBF supports development of FXIIIa blocker for thromboprophylaxis
Zedira is pursuing a new kind of mechanism for prophylaxis of thrombotic events. The lead compounds developed at Zedira open the way to small molecules targeting selectively coagulation factor XIIIa.
Inhibition of coagulation factor XIIIa, a transglutaminase, prevent the cross-linking of the fibrin fibres and the incorporation of anti-fibrinolytic factors. As opposed to the currently available therapies, the approach allows initial fibrin clotting. This prevents bleeding lowering the risk of life-threatening complications.
Preliminary studies on model systems document that factor XIIIa blockers do not obstruct the formation and aggregation of fibrin fibres but increase the fibrinolytic effects on the clot. The efficacy is even more pronounced in combination with approved fibrinolytic drugs.
The BMBF's ongoing support will enable Zedira to further bolster its technological position.
Following the successful development of a drug candidate for celiac disease, this thromboprophylaxis project also paves the way for addressing other diseases in which transglutaminases are involved.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to firstname.lastname@example.org.